Frequent epigenetics inactivation of KEAP1 gene in non-small cell lung cancer

Lucia Anna Muscarella, Paola Parrella, Vito D'Alessandro, Annamaria la Torre, Raffaela Barbano, Andrea Fontana, Antonio Tancredi, Vito Guarnieri, Teresa Balsamo, Michelina Coco, Massimiliano Copetti, Fabio Pellegrini, Patrizia de Bonis, Michele Bisceglia, Gerardo Scaramuzzi, Evaristo Maiello, Vanna Maria Valori, Giuseppe Merla, Gianluigi Vendemiale, Vito Michele Fazio

Research output: Contribution to journalArticle

Abstract

The KEAP 1/Nrf2 pathway is a master regulator of several redox-sensitive genes implicated in resistance of tumor cells against chemotherapeutic drugs. Recent data suggest that epigenetic mechanisms may play a pivotal role in the regulation of KEAP1 expression. We performed a comprehensive genetic and epigenetic analysis of the KEAP1 gene in 47 non-small cell lung cancer tissues and normal specimens. Promoter methylation analysis was performed using a quantitative methylation specific PC R assay in real time. Methylation at the KEAP1 promoter region was detected in 22 out of the 47 NSC LCs (47%) and in none of the normal tissues analyzed. Somatic mutations were detected in 7 out of the 47 tumors (15%) and loss of heterozygosity (LOH) in 10 out of the 47 (21%) of the cases. Overall, we found at least one molecular alteration in 57% of the cases. Approximately one third of the tumors had two alterations and this feature was associated with higher risk of disease progression in univariate COX regression analysis (HR = 3.62; 95% CI 1.24-10.65, p = 0.02). This result was confirmed by Kaplan-Meier analysis, which demonstrated an association between worst outcome and KEAP1 double alterations (p = 0.01, Log rank test). Our results further suggest that deregulation of the NRF2/KEAP 1 system could play a pivotal role in the cancerogenesis of NSC LC. In addition identifying patients with KEAP1 genetic and epigenetic abnormalities may contribute to disease progression prediction and response to therapy in lung cancer patients.

Original languageEnglish
Pages (from-to)710-719
Number of pages10
JournalEpigenetics
Volume6
Issue number6
DOIs
Publication statusPublished - Jun 2011

Fingerprint

Gene Silencing
Epigenomics
Non-Small Cell Lung Carcinoma
Methylation
Disease Progression
Neoplasms
Loss of Heterozygosity
Kaplan-Meier Estimate
Genetic Promoter Regions
Genes
Oxidation-Reduction
Lung Neoplasms
Regression Analysis
Mutation
Pharmaceutical Preparations
Therapeutics

Keywords

  • KEAP1
  • Methylation
  • Mutation
  • NRF2
  • NSCLC
  • Outcome

ASJC Scopus subject areas

  • Molecular Biology
  • Cancer Research

Cite this

Frequent epigenetics inactivation of KEAP1 gene in non-small cell lung cancer. / Muscarella, Lucia Anna; Parrella, Paola; D'Alessandro, Vito; la Torre, Annamaria; Barbano, Raffaela; Fontana, Andrea; Tancredi, Antonio; Guarnieri, Vito; Balsamo, Teresa; Coco, Michelina; Copetti, Massimiliano; Pellegrini, Fabio; de Bonis, Patrizia; Bisceglia, Michele; Scaramuzzi, Gerardo; Maiello, Evaristo; Valori, Vanna Maria; Merla, Giuseppe; Vendemiale, Gianluigi; Fazio, Vito Michele.

In: Epigenetics, Vol. 6, No. 6, 06.2011, p. 710-719.

Research output: Contribution to journalArticle

Muscarella, LA, Parrella, P, D'Alessandro, V, la Torre, A, Barbano, R, Fontana, A, Tancredi, A, Guarnieri, V, Balsamo, T, Coco, M, Copetti, M, Pellegrini, F, de Bonis, P, Bisceglia, M, Scaramuzzi, G, Maiello, E, Valori, VM, Merla, G, Vendemiale, G & Fazio, VM 2011, 'Frequent epigenetics inactivation of KEAP1 gene in non-small cell lung cancer', Epigenetics, vol. 6, no. 6, pp. 710-719. https://doi.org/10.4161/epi.6.6.15773
Muscarella, Lucia Anna ; Parrella, Paola ; D'Alessandro, Vito ; la Torre, Annamaria ; Barbano, Raffaela ; Fontana, Andrea ; Tancredi, Antonio ; Guarnieri, Vito ; Balsamo, Teresa ; Coco, Michelina ; Copetti, Massimiliano ; Pellegrini, Fabio ; de Bonis, Patrizia ; Bisceglia, Michele ; Scaramuzzi, Gerardo ; Maiello, Evaristo ; Valori, Vanna Maria ; Merla, Giuseppe ; Vendemiale, Gianluigi ; Fazio, Vito Michele. / Frequent epigenetics inactivation of KEAP1 gene in non-small cell lung cancer. In: Epigenetics. 2011 ; Vol. 6, No. 6. pp. 710-719.
@article{37c4900e3c1745d1a917faf1731491e3,
title = "Frequent epigenetics inactivation of KEAP1 gene in non-small cell lung cancer",
abstract = "The KEAP 1/Nrf2 pathway is a master regulator of several redox-sensitive genes implicated in resistance of tumor cells against chemotherapeutic drugs. Recent data suggest that epigenetic mechanisms may play a pivotal role in the regulation of KEAP1 expression. We performed a comprehensive genetic and epigenetic analysis of the KEAP1 gene in 47 non-small cell lung cancer tissues and normal specimens. Promoter methylation analysis was performed using a quantitative methylation specific PC R assay in real time. Methylation at the KEAP1 promoter region was detected in 22 out of the 47 NSC LCs (47{\%}) and in none of the normal tissues analyzed. Somatic mutations were detected in 7 out of the 47 tumors (15{\%}) and loss of heterozygosity (LOH) in 10 out of the 47 (21{\%}) of the cases. Overall, we found at least one molecular alteration in 57{\%} of the cases. Approximately one third of the tumors had two alterations and this feature was associated with higher risk of disease progression in univariate COX regression analysis (HR = 3.62; 95{\%} CI 1.24-10.65, p = 0.02). This result was confirmed by Kaplan-Meier analysis, which demonstrated an association between worst outcome and KEAP1 double alterations (p = 0.01, Log rank test). Our results further suggest that deregulation of the NRF2/KEAP 1 system could play a pivotal role in the cancerogenesis of NSC LC. In addition identifying patients with KEAP1 genetic and epigenetic abnormalities may contribute to disease progression prediction and response to therapy in lung cancer patients.",
keywords = "KEAP1, Methylation, Mutation, NRF2, NSCLC, Outcome",
author = "Muscarella, {Lucia Anna} and Paola Parrella and Vito D'Alessandro and {la Torre}, Annamaria and Raffaela Barbano and Andrea Fontana and Antonio Tancredi and Vito Guarnieri and Teresa Balsamo and Michelina Coco and Massimiliano Copetti and Fabio Pellegrini and {de Bonis}, Patrizia and Michele Bisceglia and Gerardo Scaramuzzi and Evaristo Maiello and Valori, {Vanna Maria} and Giuseppe Merla and Gianluigi Vendemiale and Fazio, {Vito Michele}",
year = "2011",
month = "6",
doi = "10.4161/epi.6.6.15773",
language = "English",
volume = "6",
pages = "710--719",
journal = "Epigenetics",
issn = "1559-2294",
publisher = "Taylor and Francis Inc.",
number = "6",

}

TY - JOUR

T1 - Frequent epigenetics inactivation of KEAP1 gene in non-small cell lung cancer

AU - Muscarella, Lucia Anna

AU - Parrella, Paola

AU - D'Alessandro, Vito

AU - la Torre, Annamaria

AU - Barbano, Raffaela

AU - Fontana, Andrea

AU - Tancredi, Antonio

AU - Guarnieri, Vito

AU - Balsamo, Teresa

AU - Coco, Michelina

AU - Copetti, Massimiliano

AU - Pellegrini, Fabio

AU - de Bonis, Patrizia

AU - Bisceglia, Michele

AU - Scaramuzzi, Gerardo

AU - Maiello, Evaristo

AU - Valori, Vanna Maria

AU - Merla, Giuseppe

AU - Vendemiale, Gianluigi

AU - Fazio, Vito Michele

PY - 2011/6

Y1 - 2011/6

N2 - The KEAP 1/Nrf2 pathway is a master regulator of several redox-sensitive genes implicated in resistance of tumor cells against chemotherapeutic drugs. Recent data suggest that epigenetic mechanisms may play a pivotal role in the regulation of KEAP1 expression. We performed a comprehensive genetic and epigenetic analysis of the KEAP1 gene in 47 non-small cell lung cancer tissues and normal specimens. Promoter methylation analysis was performed using a quantitative methylation specific PC R assay in real time. Methylation at the KEAP1 promoter region was detected in 22 out of the 47 NSC LCs (47%) and in none of the normal tissues analyzed. Somatic mutations were detected in 7 out of the 47 tumors (15%) and loss of heterozygosity (LOH) in 10 out of the 47 (21%) of the cases. Overall, we found at least one molecular alteration in 57% of the cases. Approximately one third of the tumors had two alterations and this feature was associated with higher risk of disease progression in univariate COX regression analysis (HR = 3.62; 95% CI 1.24-10.65, p = 0.02). This result was confirmed by Kaplan-Meier analysis, which demonstrated an association between worst outcome and KEAP1 double alterations (p = 0.01, Log rank test). Our results further suggest that deregulation of the NRF2/KEAP 1 system could play a pivotal role in the cancerogenesis of NSC LC. In addition identifying patients with KEAP1 genetic and epigenetic abnormalities may contribute to disease progression prediction and response to therapy in lung cancer patients.

AB - The KEAP 1/Nrf2 pathway is a master regulator of several redox-sensitive genes implicated in resistance of tumor cells against chemotherapeutic drugs. Recent data suggest that epigenetic mechanisms may play a pivotal role in the regulation of KEAP1 expression. We performed a comprehensive genetic and epigenetic analysis of the KEAP1 gene in 47 non-small cell lung cancer tissues and normal specimens. Promoter methylation analysis was performed using a quantitative methylation specific PC R assay in real time. Methylation at the KEAP1 promoter region was detected in 22 out of the 47 NSC LCs (47%) and in none of the normal tissues analyzed. Somatic mutations were detected in 7 out of the 47 tumors (15%) and loss of heterozygosity (LOH) in 10 out of the 47 (21%) of the cases. Overall, we found at least one molecular alteration in 57% of the cases. Approximately one third of the tumors had two alterations and this feature was associated with higher risk of disease progression in univariate COX regression analysis (HR = 3.62; 95% CI 1.24-10.65, p = 0.02). This result was confirmed by Kaplan-Meier analysis, which demonstrated an association between worst outcome and KEAP1 double alterations (p = 0.01, Log rank test). Our results further suggest that deregulation of the NRF2/KEAP 1 system could play a pivotal role in the cancerogenesis of NSC LC. In addition identifying patients with KEAP1 genetic and epigenetic abnormalities may contribute to disease progression prediction and response to therapy in lung cancer patients.

KW - KEAP1

KW - Methylation

KW - Mutation

KW - NRF2

KW - NSCLC

KW - Outcome

UR - http://www.scopus.com/inward/record.url?scp=79958702879&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79958702879&partnerID=8YFLogxK

U2 - 10.4161/epi.6.6.15773

DO - 10.4161/epi.6.6.15773

M3 - Article

C2 - 21610322

AN - SCOPUS:79958702879

VL - 6

SP - 710

EP - 719

JO - Epigenetics

JF - Epigenetics

SN - 1559-2294

IS - 6

ER -